Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma

Kuang T. Kuo, Kuan Chih Chow, Yu Chung Wu, Chen Sung Lin, Hao W. Wang, Wing Y. Li, Liang Shun Wang

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background. Esophageal cancer is one of the most aggressive malignancies in the world, and whether multiple therapeutic modalities could improve long-term survival remains controversial. Recent studies have shown an increase of cyclooxygenase-2 (COX-2) expression in various malignancies, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods. From 1993 to 1997, tissue samples from 96 patients with ESCC who underwent esophagectomy at our institution were collected for analysis. Cyclooxygenase-2 expression was examined by immunohistochemical staining, and further confirmed by Western blot analysis on six frozen tissues. Clinicopathologic data were analyzed to verify the significance. Results. Cyclooxygenase-2 immunoreactivity was detected in 59 of 96 ESCC specimens (61%), and COX-2 overexpression (COX-2 high) was observed in 49% (47 of 96) of ESCCs. Statistical differences between COX-2 high and COX-2 low were found with respect to the status of distant metastasis (M factor) (p = 0.035) and tumor stage (p = 0.04). The survival was not significantly different between patients with and without COX-2 overexpression (p = 0.43). Using the Cox regression analysis, only the N factor (p = 0.0034) and M factor (p = 0.0325) were independent prognostic factors. Conclusions. Our results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with fewer metastases and less advanced stage, but had no impact on survival. The status of local or distant lymph node metastasis was the most important prognostic factor. The biological role and pathophysiologic regulation of COX-2 overexpression in ESCC deserve further investigation.

Original languageEnglish
Pages (from-to)909-914
Number of pages6
JournalAnnals of Thoracic Surgery
Volume76
Issue number3
DOIs
Publication statusPublished - Sep 1 2003
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Neoplasm Metastasis
Survival
Esophageal Squamous Cell Carcinoma
Far-Western Blotting
Neoplasms
Esophagectomy
Esophageal Neoplasms
Lymph Nodes
Regression Analysis
Staining and Labeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. / Kuo, Kuang T.; Chow, Kuan Chih; Wu, Yu Chung; Lin, Chen Sung; Wang, Hao W.; Li, Wing Y.; Wang, Liang Shun.

In: Annals of Thoracic Surgery, Vol. 76, No. 3, 01.09.2003, p. 909-914.

Research output: Contribution to journalArticle

Kuo, Kuang T. ; Chow, Kuan Chih ; Wu, Yu Chung ; Lin, Chen Sung ; Wang, Hao W. ; Li, Wing Y. ; Wang, Liang Shun. / Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. In: Annals of Thoracic Surgery. 2003 ; Vol. 76, No. 3. pp. 909-914.
@article{1054bc50c4dc4e44ac7f434bc2ceda48,
title = "Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma",
abstract = "Background. Esophageal cancer is one of the most aggressive malignancies in the world, and whether multiple therapeutic modalities could improve long-term survival remains controversial. Recent studies have shown an increase of cyclooxygenase-2 (COX-2) expression in various malignancies, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods. From 1993 to 1997, tissue samples from 96 patients with ESCC who underwent esophagectomy at our institution were collected for analysis. Cyclooxygenase-2 expression was examined by immunohistochemical staining, and further confirmed by Western blot analysis on six frozen tissues. Clinicopathologic data were analyzed to verify the significance. Results. Cyclooxygenase-2 immunoreactivity was detected in 59 of 96 ESCC specimens (61{\%}), and COX-2 overexpression (COX-2 high) was observed in 49{\%} (47 of 96) of ESCCs. Statistical differences between COX-2 high and COX-2 low were found with respect to the status of distant metastasis (M factor) (p = 0.035) and tumor stage (p = 0.04). The survival was not significantly different between patients with and without COX-2 overexpression (p = 0.43). Using the Cox regression analysis, only the N factor (p = 0.0034) and M factor (p = 0.0325) were independent prognostic factors. Conclusions. Our results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with fewer metastases and less advanced stage, but had no impact on survival. The status of local or distant lymph node metastasis was the most important prognostic factor. The biological role and pathophysiologic regulation of COX-2 overexpression in ESCC deserve further investigation.",
author = "Kuo, {Kuang T.} and Chow, {Kuan Chih} and Wu, {Yu Chung} and Lin, {Chen Sung} and Wang, {Hao W.} and Li, {Wing Y.} and Wang, {Liang Shun}",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S0003-4975(03)00717-3",
language = "English",
volume = "76",
pages = "909--914",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma

AU - Kuo, Kuang T.

AU - Chow, Kuan Chih

AU - Wu, Yu Chung

AU - Lin, Chen Sung

AU - Wang, Hao W.

AU - Li, Wing Y.

AU - Wang, Liang Shun

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background. Esophageal cancer is one of the most aggressive malignancies in the world, and whether multiple therapeutic modalities could improve long-term survival remains controversial. Recent studies have shown an increase of cyclooxygenase-2 (COX-2) expression in various malignancies, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods. From 1993 to 1997, tissue samples from 96 patients with ESCC who underwent esophagectomy at our institution were collected for analysis. Cyclooxygenase-2 expression was examined by immunohistochemical staining, and further confirmed by Western blot analysis on six frozen tissues. Clinicopathologic data were analyzed to verify the significance. Results. Cyclooxygenase-2 immunoreactivity was detected in 59 of 96 ESCC specimens (61%), and COX-2 overexpression (COX-2 high) was observed in 49% (47 of 96) of ESCCs. Statistical differences between COX-2 high and COX-2 low were found with respect to the status of distant metastasis (M factor) (p = 0.035) and tumor stage (p = 0.04). The survival was not significantly different between patients with and without COX-2 overexpression (p = 0.43). Using the Cox regression analysis, only the N factor (p = 0.0034) and M factor (p = 0.0325) were independent prognostic factors. Conclusions. Our results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with fewer metastases and less advanced stage, but had no impact on survival. The status of local or distant lymph node metastasis was the most important prognostic factor. The biological role and pathophysiologic regulation of COX-2 overexpression in ESCC deserve further investigation.

AB - Background. Esophageal cancer is one of the most aggressive malignancies in the world, and whether multiple therapeutic modalities could improve long-term survival remains controversial. Recent studies have shown an increase of cyclooxygenase-2 (COX-2) expression in various malignancies, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods. From 1993 to 1997, tissue samples from 96 patients with ESCC who underwent esophagectomy at our institution were collected for analysis. Cyclooxygenase-2 expression was examined by immunohistochemical staining, and further confirmed by Western blot analysis on six frozen tissues. Clinicopathologic data were analyzed to verify the significance. Results. Cyclooxygenase-2 immunoreactivity was detected in 59 of 96 ESCC specimens (61%), and COX-2 overexpression (COX-2 high) was observed in 49% (47 of 96) of ESCCs. Statistical differences between COX-2 high and COX-2 low were found with respect to the status of distant metastasis (M factor) (p = 0.035) and tumor stage (p = 0.04). The survival was not significantly different between patients with and without COX-2 overexpression (p = 0.43). Using the Cox regression analysis, only the N factor (p = 0.0034) and M factor (p = 0.0325) were independent prognostic factors. Conclusions. Our results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with fewer metastases and less advanced stage, but had no impact on survival. The status of local or distant lymph node metastasis was the most important prognostic factor. The biological role and pathophysiologic regulation of COX-2 overexpression in ESCC deserve further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0042331532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042331532&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(03)00717-3

DO - 10.1016/S0003-4975(03)00717-3

M3 - Article

C2 - 12963227

AN - SCOPUS:0042331532

VL - 76

SP - 909

EP - 914

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -